SavedAdd your journal

Journals / Nöropsikiyatri Arşivi / 2009 / Cilt: 46 - Sayı: 1

Quetiapine administration for the management of psychosis in juvenile parkinson’s disease: A case report

Juvenil parkinson tedavisi sürecinde gelişen psikozda ketiapin kullanımı: Bir olgu sunumu

Esra SEZGİN
Nesrin B. TOMRUK
Nihat ALPAY
Pages
24–26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, a case of JP in whom psychotic symptoms have developed after twenty years of antiparkinsonian therapy is discussed in order to address management strategies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Parkinson's disease (PD), which generally has a late onset (between age 50 and 60), is a chronic disease with a gradual progression.
📊
Key Findings & Data:Juvenile Parkinson’s disease (JP) describes Parkinsonism manifesting before age 21.
💡
Conclusion & Impact:In this article, a case of JP in whom psychotic symptoms have developed after twenty years of antiparkinsonian therapy is discussed in order to address management strategies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Psikotik bozukluklar · Antiparkinson ajanlar · Erişkin

Abstract

Parkinson's disease (PD), which generally has a late onset (between age 50 and 60), is a chronic disease with a gradual progression. Juvenile Parkinson’s disease (JP) describes Parkinsonism manifesting before age 21. There is a high incidence of positive family history in JP. Besides motor symptoms, psychiatric disorders/ symptoms such as depression, anxiety, psychosis and sleep disturbances are also prevalent, in PD patients. Psychosis may be related to long term antiparkinsonian treatment. In this article, a case of JP in whom psychotic symptoms have developed after twenty years of antiparkinsonian therapy is discussed in order to address management strategies.

Özet

Parkinson Hastalığı (PH) genellikle 50-60 yaşları arasında başlayan yavaş, progresif seyirli kronik bir hastalıktır. Parkinson tablosu 21 yaşından önce başlarsa Juvenil Parkinson Hastalığı (JP) olarak adlandırılır. JP’de pozitif aile öyküsü sık görülür. PH’da motor semptomların dışında depresyon, anksiyete, psikoz, uyku bozuklukları gibi psikiyatrik semptomlar da yaygındır. Psikoz gelişimi uzun süreli antiparkinson tedaviyle ilişkili olabilir. Bu yazıda 20 yıldan uzun süredir antiparkinson ajanlarla tedavi edilirken psikotik belirtiler gösteren bir JP olgusu tedavi stratejileri bağlamında tartışılmaktadır.

🔖

Cite This Article

SEZGİN, E., TOMRUK, N. B., ALPAY, N. (2009). Quetiapine administration for the management of psychosis in juvenile parkinson’s disease: A case report. Nöropsikiyatri Arşivi, Cilt: 46 - Sayı: 1, 24–26. https://ajindex.com/articles/292763

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Uc EY, Rodnitzky RL. Juvenile Parkinsonism. Seminars in Pediatric Neurology 2003; 10: 62-7
  2. Chacon J, Dinca-Avarvarei L, Acosta J et al. Early-onset Parkinsonism: A report on a Spanish series. Rev Neurol 2007; 45: 323-7
  3. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 2006; 5:355-63
  4. Schrag A, Ben-Shlomo Y, Brown R et al. Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality. Mov Disord 1998; 13: 885-94
  5. Thanvi BR, Munshi SK, Vijaykumar N. Neuropsychiatric non-motor aspects of Parkinson’s disease. Postgrad Med J 2003; 79: 561-5
  6. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992; 7: 125-31
  7. Rabey JM, Treves TA, Neufeld MY et al. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson’s disease. Neurology 1995; 45: 432-4
  8. Friedman A, Sienkiewicz J. Psychotic complications of long-term levodopa treatment of Parkinson’s disease. Acta Neurol Scand 1991; 84: 111-3
  9. Wagner ML, Fedak MN, Sage JI et al. Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease. Ann Clin Lab Sci 1996; 26: 389-95
  10. Klawans HL. Psychiatric side effects during the treatment of Parkinson's disease. J Neural Transm Suppl 1988; 27: 117-22
  11. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003; 26: 643-59
  12. Pollak P. Psychic disorders. Rev Neurol (Paris) 2002; 158:125-31 (article in French)
  13. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 2000; 20: 54-60
  14. Molho ES, Factor SA. Parkinson's disease: the treatment of drug-induced hallucinations and psychosis. Curr Neurol Neurosci Rep 2001; 1: 320-8
  15. Miyasaki JM, Shannon K, Voon V, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996-1002
  16. Factor SA, Brown D, Molho ES et al. Clozapine: a 2-year open trial in Parkinson’s disease patients with psychosis. Neurology 1994; 44: 544-6.